Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Earlier this week, the board of directors of CBOE Holdings Inc. ( CBOE - Snapshot Report ) announced a special cash dividend of 75 cents per share payable on Dec 28, 2012 to shareholders of record as of Dec 21, 2012. This implies a dividend yield of 2.5%, based on the company’s closing share price of $30.00 as of Dec 13, 2012.
CBOE expects a cash outlay of about $66.6 million for the dividend payment, considering the number of shares outstanding at present. The company will use its cash-in-hand to pay the dividend.
This will substantially reduce CBOE’s cash and cash equivalents, which stood at $160.3 million as of Sep 30, 2012. However, the company generated operating cash flow of $140.87 million during the first nine months of 2012, which is sufficient to cover the expenditure for the special dividend.
The strong cash flows generated by CBOE along with the absence of debt have resulted in a sturdy balance sheet and abundant free cash. Consequently, the company strives to regularly return the excess capital to shareholders through dividends and share repurchases, apart from investing in business.
In addition to this special dividend, CBOE declared a regular quarterly dividend on Oct 30, 2012. This cash dividend of 15 cents per share (for the fourth quarter of 2012) will be paid on Dec 21, 2012 to shareholders of record as of Nov 30, 2012.
Apart from dividend payments, CBOE used its excess capital for share buybacks. The company repurchased 1.87 million shares at an average price of $26.58 per share up to Nov 1 this year. This involved a cash outlay of $49.7 million. As of Sep 30, 2012, outstanding balance in the company’s share repurchase program stood at $103.3 million.
Other exchanges, such as Nasdaq OMX Group Inc. ( NDAQ - Analyst Report ) and NYSE Euronext Inc. ( NYX - Analyst Report ) also regularly deploy capital via share repurchases and dividend payments. Currently, CBOE carries a Zacks #3 Rank (Hold). We maintain a long-term ‘Neutral’ recommendation on the stock.
Read the full reports :
Analyst Report on NDAQ
Analyst Report on NYX
Snapshot Report on CBOE